Bayesian Capital Management’s Puma Biotechnology PBYI Stock Holding History

Bayesian Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-17,700	Closed	-$54K	–	880
2024 Q4	$54K	Buy	+17,700	New	+$51.5K	0.01%	630
2023 Q1	–	Sell	-11,901	Closed	-$50.3K	–	1020
2022 Q4	$50.3K	Buy	+11,901	New	+$41.1K	0.01%	704
2020 Q3	–	Sell	-10,700	Closed	-$112K	–	649
2020 Q2	$112K	Buy	+10,700	New	+$111K	0.02%	473
2020 Q1	–	Sell	-17,019	Closed	-$149K	–	928
2019 Q4	$149K	Buy	+17,019	New	+$141K	0.03%	554
2019 Q3	–	Sell	-15,000	Closed	-$191K	–	645
2019 Q2	$191K	Sell	15,000 -3,575	-19%	-$82.3K	0.04%	443
2019 Q1	$721K	Buy	+18,575	New	+$567K	0.14%	209
2018 Q2	–	Sell	-7,500	Closed	-$510K	–	683
2018 Q1	$510K	Buy	+7,500	New	+$562K	0.13%	264

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bayesian Capital Management's PBYI Position: Q1 2025 in Review

Bayesian Capital Management sold out of Puma Biotechnology (PBYI) in Q1 2025, closing a stake of 17,700 shares — an estimated $54K sold.

Bayesian Capital Management first reported a position in PBYI in Q1 2018 and held it in 7 quarters. The position peaked at $721K in Q1 2019. 116 funds tracked by Wall St. Rank hold PBYI as of Q1 2025.

Bayesian Capital Management reported no remaining Puma Biotechnology position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 17,700 Puma Biotechnology shares in Q1 2025, an estimated $54K.
Bayesian Capital Management first reported a position in Puma Biotechnology in Q1 2018 and held it in 7 quarters.
Bayesian Capital Management's Puma Biotechnology position peaked at $721K in Q1 2019.
116 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.